Egham, United Kingdom

Amninder Sangha

This inventor holds 2 USPTO granted patents. Top assignee: Teesside University. Active years: 2023-2026.


% Patents Active = 50.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2023-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Amninder Sangha: Innovator in Neurodegenerative Disorder Treatments

Amninder Sangha is a notable inventor based in Egham, GB. He has made significant contributions to the field of neurodegenerative disorders through his innovative research and inventions. His work focuses on developing novel therapies for conditions such as Alzheimer's disease.

Latest Patents

Amninder Sangha holds a patent related to neurodegenerative disorders. This invention involves novel oligonucleotides designed for treating such conditions. The patent provides antisense oligonucleotides and compositions that can be used in therapies and methods for addressing neurodegenerative disorders. Additionally, the invention incorporates genome editing techniques to achieve results similar to those obtained with the novel antisense oligonucleotides.

Career Highlights

Amninder Sangha is affiliated with Teesside University, where he continues to advance his research in neurodegenerative disorders. His work has garnered attention for its potential impact on treatment options for patients suffering from these debilitating conditions.

Collaborations

Some of his notable coworkers include Pavlos Alifragis and Linda Popplewell. Their collaborative efforts contribute to the ongoing research and development in the field of neurodegenerative disorders.

Conclusion

Amninder Sangha's innovative work in developing treatments for neurodegenerative disorders highlights his commitment to advancing medical science. His contributions are paving the way for new therapeutic options that could significantly improve the lives of those affected by such conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…